|Drug Name (Ref. #)||Indication (Sponsor)||Key Trial Characteristics||Reason for Discontinuation|
|Cariporide (20)||Unstable angina and non–ST-segment elevation MI∗ (Sanofi-Aventis)||Randomized, double-blind||Placebo||Death or MI at 36 days||Failure to demonstrate efficacy (no significant improvement vs. placebo)|
|Darusentan||Treatment-resistant hypertension (Gilead/Abbott)||Randomized, double-blind||Placebo||Changes in sitting systolic and diastolic blood pressures||Failure to demonstrate efficacy in second pivotal trial (no significant change in blood pressure)|
|Lotrafiban (21)||Acute coronary syndrome (GlaxoSmithKline)||Randomized, double-blind||Placebo||Death, MI, stroke, severe recurrent ischemia, and urgent revascularization||Halted due to safety concerns (increased risk of death and serious bleeding)|
|Nolomirole (22)||Heart failure (Chiesi)||Randomized, double-blind||Placebo||Time to death or hospitalization for heart failure||Failure to demonstrate efficacy (no significant improvement vs. placebo)|
|Torcetrapib (23)||Prevention of cardiovascular disease (Pfizer)||Randomized, double-blind||Atorvastatin||Time to first major cardiovascular event†||Halted due to safety concerns (increased risk of death and cardiovascular events)|
MI = myocardial infarction.
↵∗ The inclusion criteria for the cariporide trial also included patients undergoing a high-risk percutaneous coronary intervention or coronary artery bypass surgery.
↵† The primary outcome was the time to the first occurrence of a major cardiovascular event, a composite that included 4 components: death from coronary heart disease (defined as fatal MI excluding procedure-related events, fatal heart failure, sudden cardiac death, or other cardiac death), nonfatal MI (excluding procedure-related events), stroke, and hospitalization for unstable angina.